XTL Biopharmaceuticals Ltd ADR Market Cap ($8.80 Million)
Market Cap & Net Worth: XTL Biopharmaceuticals Ltd ADR (XTLB)
XTL Biopharmaceuticals Ltd ADR market cap. XTL Biopharmaceuticals Ltd ADR (NASDAQ:XTLB) has a market capitalization of $8.80 Million ($8.80 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27279 globally and #5666 in its home market, demonstrating a 2.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XTL Biopharmaceuticals Ltd ADR's stock price $2.45 by its total outstanding shares 9462434 (9.46 Million). Also see XTL Biopharmaceuticals Ltd ADR cash conversion from operations for how efficiently the company converts equity into cash flow.
XTL Biopharmaceuticals Ltd ADR Market Cap History (2015–2026)
XTL Biopharmaceuticals Ltd ADR market cap history from 2015 to 2026. Data shows change from $66.71 Million to $15.23 Million (-12.11% CAGR). Check XTL Biopharmaceuticals Ltd ADR stock quote for real-time trading data and today's change.
Index Memberships
XTL Biopharmaceuticals Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #769 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2502 of 3165 |
Weight: XTL Biopharmaceuticals Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
XTL Biopharmaceuticals Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XTL Biopharmaceuticals Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of XTL Biopharmaceuticals Ltd ADR to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
42.50x
XTL Biopharmaceuticals Ltd ADR's market cap is 42.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $30.02 Million | $23.00K | -$2.54 Million | 1305.40x | N/A |
| 2017 | $21.64 Million | $29.00K | -$781.00K | 746.29x | N/A |
| 2018 | $16.37 Million | $52.00K | $2.99 Million | 314.81x | 5.48x |
| 2019 | $12.96 Million | $69.00K | -$1.35 Million | 187.88x | N/A |
| 2020 | $28.67 Million | $28.00K | -$782.00K | 1023.97x | N/A |
| 2021 | $26.21 Million | $1.47 Million | $435.00K | 17.88x | 60.26x |
| 2022 | $11.45 Million | $-459.00K | -$1.35 Million | -24.94x | N/A |
| 2024 | $19.17 Million | $451.00K | -$1.03 Million | 42.50x | N/A |
Competitor Companies of XTLB by Market Capitalization
Companies near XTL Biopharmaceuticals Ltd ADR in the global market cap rankings as of November 3, 2026. Also see how large is XTL Biopharmaceuticals Ltd ADR's balance sheet for a full breakdown of the balance sheet.
Key companies related to XTL Biopharmaceuticals Ltd ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of XTL Biopharmaceuticals Ltd ADR (2015–2026)
Market capitalization of XTL Biopharmaceuticals Ltd ADR from 2015 to today. Between 2015 and today, XTL Biopharmaceuticals Ltd ADR's market cap moved from $66.71 Million to $ 15.23 Million, with a yearly change of -12.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.23 Million | +177.59% |
| 2025 | $5.49 Million | -71.37% |
| 2024 | $19.17 Million | +100.55% |
| 2023 | $9.56 Million | -16.52% |
| 2022 | $11.45 Million | -56.32% |
| 2021 | $26.21 Million | -8.58% |
| 2020 | $28.67 Million | +121.17% |
| 2019 | $12.96 Million | -20.81% |
| 2018 | $16.37 Million | -24.36% |
| 2017 | $21.64 Million | -27.92% |
| 2016 | $30.02 Million | -54.99% |
| 2015 | $66.71 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of XTL Biopharmaceuticals Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.80 Million USD |
| MoneyControl | $8.80 Million USD |
| MarketWatch | $8.80 Million USD |
| marketcap.company | $8.80 Million USD |
| Reuters | $8.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more